#FDANews: The FDA has approved daratumumab and hyaluronidase-fihj (Darzalex Faspro) for the treatment of adult patients with high-risk smoldering multiple myeloma.📣 🔗: https://t.co/zQ50jjwQiR

👨‍⚕️Afternoon Watch: Jason S. Starr, DO, discusses the significance of the extrapancreatic neuroendocrine tumor cohort of the phase 3 CABINET trial (NCT03375320) of cabozantinib. 💡 #CancerResearch #OncologyNews 🔗:

#ESMO25: Nivolumab plus visugromab showed superior efficacy to placebo and good tolerability in patients with newly diagnosed muscle-invasive bladder cancer, according to GDFATHER-NEO trial results.💡 🔗:

🌐 Results from the phase 1 RaDD trial radiotherapy added to immunotherapy enhanced responses, demonstrated manageable safety, and was informed by T-cell dysregulation in patients with B-cell lymphomas. ✔️ Read the full trial results here:

📣 FDA News: The FDA has granted orphan drug designation to the acute myeloid leukemia treatment candidate M2T-CD33 (LTI-214), signaling a potential entrance for a novel, differentiated therapeutic approach to this aggressive disease.💡 🔗: https://t.co/UcQO0ckjnj

Thank you Coach Devaney @KyleDevaney17 and UTEP Football for the Game day invite. Super Blessed for this opportunity. Go Miners!!!!! @MaranaFB @CoachSWUTEP @CoachBobbyDaly @MaranaAthletics @CoachSteward__

☀️Morning Watch: Dr. Michael Soulen discusses the safety and efficacy regarding the novel combined treatment for neuroendocrine tumors that utilizes both systemic chemotherapy and peptide receptor radionuclide therapy at the 2025 NANETS Symposium.🌐 🔗:

💡 EDGE-Gastric trial: The combination of domvanalimab and zimberelimab showed a 59% objective response rate in advanced HER2-negative gastroesophageal cancer patients, with a median overall survival of 26.7 months. 🔗:

💡 TRIMM-2 Study: Talquetamab and daratumumab combination achieved an 82.4% overall response rate in relapsed/refractory multiple myeloma patients, with a median PFS of 21.2 months. Read the full trial results here:

#ESMO2025: A novel combination therapy shows promise for preserving kidneys in high-risk upper tract urothelial carcinoma, challenging traditional treatment methods. #Kidney #UrothelialCarcinoma

📹 WATCH: Experts explore a novel combined therapy for liver-dominant #neuroendocrine tumors, enhancing treatment durability with chemotherapy and PRRT. #NANETS2025

📹 WATCH: Dr. Jonathan Strosberg discusses the promising results of the ALPHAMEDIX-02 trial, evaluating a new therapy for advanced neuroendocrine tumors. #NANETS2025

🫁 New data reveals lifileucel shows promising efficacy and safety in treating advanced non-small cell #LungCancer, paving the way for potential FDA approval. #NSCLC

Camizestrant shows promising antitumor activity and tolerability when combined with CDK4/6 inhibitors in advanced ER+, HER2– #BreastCancer patients.

Bexmarilimab combined with azacitidine shows promising efficacy and safety in high-risk myelodysplastic syndrome, paving the way for new treatment options. #MDS #Oncology #ClinicalTrials

💡With 4 approved androgen receptor pathway inhibitors in use in combination w/ androgen deprivation therapy for metastatic hormone-sensitive prostate cancer, the differences in tolerability, quality of life, etc are of greater interest to oncologists. 🔗

📣 Sevabertinib demonstrates promising safety and efficacy in treating non-small cell lung cancer with HER2 or EGFR mutations, offering hope for patients. #OncologyNews #CancerResearch 🔗: https://t.co/q2ZDOkWTHf

GraniteShares announced distribution rates for the YieldBOOST™ TSLA ETF (TSYY) as of November 06, 2025 $TSYY TSYY: Standardized performance: Since Inception (12/18/2024): -8.10%

💡 Vorasidenib shows significant long-term benefits for IDH-mutant glioma patients, enhancing survival and delaying treatment needs post-surgery. 🔗: https://t.co/XW3OomvKee

✔️ Community-based CAR T-cell therapy expands access to innovative cancer treatments, improving patient outcomes and reducing hospital stays for blood cancer patients. #CancerInnovation #OncologyNews 🔗:

💡 Whole-genome sequencing uncovers critical genomic insights in salivary gland cancer, paving the way for targeted therapies and improved patient outcomes. Read more about the trial outcomes here:

📣 New research reveals that CD26+ leukemia stem cell levels at diagnosis predict treatment response in chronic myeloid leukemia patients, enhancing TKI therapy strategies. #CancerResearch #OncologyNews 🔗: